FOLLOWUS
Effects of herbal compound 861 on collagen synthesis and degradation in rat mesangial cells exposed to high glucose
Effects of herbal compound 861 on collagen synthesis and degradation in rat mesangial cells exposed to high glucose
- 中国结合医学杂志（英文版） 2014年20卷第3期 页码：209-215
- Affiliations：
Department of Gerontology, Beijing Friendship Hospital, Capital Medical University,Beijing,China
- Author bio：
- Funds：
DOI：10.1007/s11655-014-1741-6
中图分类号：纸质出版日期：2014，
网络出版日期：2014-3-4，
Scan for full text
Ma, Q., Zhang, L., Yao, L. et al. Effects of herbal compound 861 on collagen synthesis and degradation in rat mesangial cells exposed to high glucose., Chin. J. Integr. Med. 20, 209–215 (2014). https://doi.org/10.1007/s11655-014-1741-6
Qing Ma, Li Zhang, Lan Yao, et al. Effects of herbal compound 861 on collagen synthesis and degradation in rat mesangial cells exposed to high glucose[J]. Chinese Journal of Integrative Medicine, 2014,20(3):209-215.
Ma, Q., Zhang, L., Yao, L. et al. Effects of herbal compound 861 on collagen synthesis and degradation in rat mesangial cells exposed to high glucose., Chin. J. Integr. Med. 20, 209–215 (2014). https://doi.org/10.1007/s11655-014-1741-6 DOI：
Qing Ma, Li Zhang, Lan Yao, et al. Effects of herbal compound 861 on collagen synthesis and degradation in rat mesangial cells exposed to high glucose[J]. Chinese Journal of Integrative Medicine, 2014,20(3):209-215. DOI： 10.1007/s11655-014-1741-6.
摘要
To investigate the effects of Herbal Compound 861 (Cpd 861) on collagen synthesis and degradation in rat mesangial cells exposed to high glucose. The third to fifth passage of rat mesangial cells were exposed to high glucose and Cpd 861 at a concentration of 0.25–4.00 g/L for 24
48 and 72 h
respectively. Benazepril (10−7–10−3 mmol/L) was selected as positive control. The methyl thiazolyl tetrazolium colorimetric assay was used to evaluate the effect of Cpd 861 on cell proliferation. After incubation with Cpd 861 at a concentration of 2.00 g/L for 48 h
the protein secretions of collagen type IV
matrix metallopeptidase 9 (MMP-9)
tissue inhibitor of metalloproteinase-1 (TIMP-1)
transforming growth factor beta 1 (TGF-β1)
and hepatocyte growth factor (HGF) were detected by enzyme-linked immunosorbent assay method. And rat mesangial cells were harvested to determine MMP-9
TIMP-1
TGF-β1 and HGF mRNA expression by reverse transcription polymerase chain reaction. Cpd 861 inhibited cell proliferation induced by high glucose in a dose- and time-dependent manner. Compared with high glucose
collagen type IV production was decreased significantly by Cpd 861 (P<0.01). Cpd 861 increased the protein secretions and mRNA expressions of MMP-9 and HGF
whereas the protein secretions and mRNA expressions of TIMP-1 and TGF-β1 were reduced markedly (P<0.05). The ratio of MMP-9 to TIMP-1 was enhanced by Cpd 861 significantly. There was no significant difference in all above-mentioned effects between Cpd 861 (2.00 g/L) and benazepril (10−5 mmol/L). The anti-glomerulosclerosis mechanisms of Cpd 861 were partly attributed to its effects of inhibiting mesangial cell proliferation
decreasing collagen synthesis and enhancing collagen degradation.
Abstract
To investigate the effects of Herbal Compound 861 (Cpd 861) on collagen synthesis and degradation in rat mesangial cells exposed to high glucose. The third to fifth passage of rat mesangial cells were exposed to high glucose and Cpd 861 at a concentration of 0.25–4.00 g/L for 24
48 and 72 h
respectively. Benazepril (10−7–10−3 mmol/L) was selected as positive control. The methyl thiazolyl tetrazolium colorimetric assay was used to evaluate the effect of Cpd 861 on cell proliferation. After incubation with Cpd 861 at a concentration of 2.00 g/L for 48 h
the protein secretions of collagen type IV
matrix metallopeptidase 9 (MMP-9)
tissue inhibitor of metalloproteinase-1 (TIMP-1)
transforming growth factor beta 1 (TGF-β1)
and hepatocyte growth factor (HGF) were detected by enzyme-linked immunosorbent assay method. And rat mesangial cells were harvested to determine MMP-9
TIMP-1
TGF-β1 and HGF mRNA expression by reverse transcription polymerase chain reaction. Cpd 861 inhibited cell proliferation induced by high glucose in a dose- and time-dependent manner. Compared with high glucose
collagen type IV production was decreased significantly by Cpd 861 (P<0.01). Cpd 861 increased the protein secretions and mRNA expressions of MMP-9 and HGF
whereas the protein secretions and mRNA expressions of TIMP-1 and TGF-β1 were reduced markedly (P<0.05). The ratio of MMP-9 to TIMP-1 was enhanced by Cpd 861 significantly. There was no significant difference in all above-mentioned effects between Cpd 861 (2.00 g/L) and benazepril (10−5 mmol/L). The anti-glomerulosclerosis mechanisms of Cpd 861 were partly attributed to its effects of inhibiting mesangial cell proliferation
decreasing collagen synthesis and enhancing collagen degradation.
关键词
Herbal Compound 861mesangial cellscollagen type IVmatrix metalloproteinasecytokine
Keywords
Herbal Compound 861mesangial cellscollagen type IVmatrix metalloproteinasecytokine
references
Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 2008;233:4–11.
Umezono T, Toyoda M, Kato M, Miyauchi M, Kimura M, Maruyama M, et al. Glomerular expression of CTGF, TGFbeta 1 and type IV collagen in diabetic nephropathy. J Nephrol 2006;19:751–757.
Ihm C, Lee GS, Nast CC, Artishevsky A, Guillermo R, Levin PS, et al. Early increased renal procollagen 1 (IV) mRNA levels in streptozotocin-induced diabetes. Kidney Int 1992;41:768–777.
Pugliese G, Pricci F, Pugliese F, Mene P, Lenti L, Andreani D, et al. Mechanisms of glucose-enhanced extracellular matrix accumulation in rat glomerular mesangial cells. Diabetes 1994;43:478–490.
Schnaper HW. Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis. PediatrNephrol 1995;9:104–111.
Han SY, Jee YH, Han KH, Kang YS, Kim HK, Han JY, et al. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol Dial Transplant 2006;21:2406–2416.
Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562–573.
Thrailkill KM, Clay Bunn R, Fowlkes JL. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine 2009;35:1–10.
Qin YH, Lei FY, Hu P, Pei J, Feng ZB, Pang YS. Effect of all-trans retinoic acid on renal expressions of matrix metalloproteinase-2, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rats with glomerulosclerosis. Pediatr Nephrol 2009;24:1477–1486.
Chromek M, Tullus K, Hertting O, Jaremko G, Khalil A, Li YH, et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in acute pyelonephritis and renal scarring. Pediatr Res 2003;53:698–705.
Qi W, Twigg S, Chen X, Polhill TS, Poronnik P, Gilbert RE, et al. Integrated actions of transforming growth factor-beta 1 and connective tissue growth factor in renal fibrosis. Am J Physiol Renal Physiol 2005;288:F800–F809.
Baricos WH, Cortez SL, Deboisblanc M, Xin S. Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 1999;10:790–795.
Liu Y, Rajur K, Tolbert E, Dworkin LD. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int 2000;58:2028–2043.
Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 2004;287:F7–F16.
Wang BE, Wang TL, Jia JD, Ma H, Duan ZP, Li XM, et al. Experiment and clinical study on inhibition and reversion of liver fibrosis with integrated Chinese and Western medicine. Chin J Integr Tradit West Med (Chin) 1999;19:6–11.
Yin SS, Wang BE, Wang TL, Jia JD, Qian LX. The effect of Cpd 861 on chronic hepatitis B related fibrosis and early cirrhosis: a randomized, double blind, placebo controlled clinical trial. Chin J Hepatol (Chin) 2004;12:467–470.
Wang TL, Wang BE, Zhang HH, Liu X, Duan ZP, Zhang J, et al. Pathological study of the therapeutic effect on HBV-related liver fibrosis with herbal compound 861. Chin J Gastroenterol Hepatol (Chin) 1998;7:148–153.
Wang L, Wang BE, Wang J, Xiao PG, Tan XH. Herbal compound 861 regulates mRNA expression of collagen synthesis- and degradation-related genes in human hepatic stellate cells. World J Gastroenterol 2008;14:1790–1794.
Chen HP, Zhang QD, Wang BE. Protective effects of compound 861 on diabetic nephropathy in STZ-induced diabetic rats. Chin J Integr Tradit West Nephrol (Chin) 2007;8:328–332.
Consolo M, Amoroso A, Spandidos DA, Mazzarino MC. Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease. Int J Mol Med 2009;24:143–152.
Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC. TGFbeta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 2003;284:F243–F252.
Dai C, Liu Y. Hepatocyte growth factor antagonizes the profibrotic action of TGF-beta 1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J Am Soc Nephrol 2004;15:1402–1412.
Inoue T, Okada H, Kobayashi T, Watanabe Y, Kanno Y, Kopp JB, et al. Hepatocyte growth factor counteracts transforming growth factor-beta1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice. FASEB J 2003;17:268–270.
Tsau YK, Tsai IJ, Chen YM. Transient reciprocal change of renal hepatocyte growth factor and transforming growth factorbeta1 may relate to renal hypertrophy in rats with liver injury or unilateral nephrectomy. Pediatr Res 2006;59:494–499.
Capuano A, Costanzi S, Peluso G, Zannoni G, Vellone VG, Gremese E, et al. Hepatocyte growth factor and transforming growth factor beta1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. Arthritis Rheum 2006;54:3633–3639.
Hilgers KF, Dötsch J, Rascher W, Mann JF. Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol 2004;19:956–961.
Mangrum AJ, Bakris GL. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol 2004;24:168–175.
Sun SZ, Wang Y, Li Q, Tian YJ, Liu MH, Yu YH. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats. Chin Med J 2006;119:814–821.
0
浏览量
665
Downloads
0
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 邮编：100091
- 联系电话：010-62886827, 62877592 传真：010-62874291
- 技术支持由北京北大方正电子有限公司提供 京ICP备05067934号-1
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
